Ubs Group Ag Beam Therapeutics Inc. Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Ubs Group Ag holds 1,461,789 shares of BEAM stock, worth $23.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,461,789

Previous 1,819,636 19.67%

Holding current value

$23.1 Million

Previous $45.1 Million 36.74%

% of portfolio

0.01%

Previous 0.01%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	SELL	$19.53 - $34.09 $6.99 Million - $12.2 Million	-357,847 Reduced 19.67%	1,461,789 $28.5 Million
Q4 2024 Feb 14, 2025	BUY	$21.55 - $30.35 $35.1 Million - $49.5 Million	1,630,442 Added 861.78%	1,819,636 $45.1 Million
Q3 2024 Nov 14, 2024	BUY	$22.57 - $33.14 $600,745 - $882,087	26,617 Added 16.37%	189,194 $4.64 Million
Q2 2024 Aug 13, 2024	SELL	$21.22 - $32.66 $1.86 Million - $2.86 Million	-87,664 Reduced 35.03%	162,577 $3.81 Million
Q1 2024 May 13, 2024	SELL	$23.46 - $45.07 $240,676 - $462,373	-10,259 Reduced 3.94%	250,241 $8.27 Million
Q4 2023 Feb 09, 2024	BUY	$17.69 - $30.76 $2.5 Million - $4.34 Million	141,102 Added 118.18%	260,500 $7.09 Million
Q3 2023 Nov 09, 2023	SELL	$23.01 - $32.46 $179,662 - $253,447	-7,808 Reduced 6.14%	119,398 $2.87 Million
Q2 2023 Aug 11, 2023	BUY	$29.32 - $35.99 $2.17 Million - $2.66 Million	73,921 Added 138.73%	127,206 $4.06 Million
Q1 2023 May 12, 2023	SELL	$30.15 - $48.79 $2.58 Million - $4.17 Million	-85,420 Reduced 61.58%	53,285 $1.63 Million
Q4 2022 Feb 08, 2023	BUY	$36.73 - $51.6 $4.79 Million - $6.74 Million	130,546 Added 1600.02%	138,705 $5.42 Million
Q3 2022 Nov 10, 2022	SELL	$39.79 - $70.31 $1.25 Million - $2.21 Million	-31,393 Reduced 79.37%	8,159 $389,000
Q2 2022 Aug 10, 2022	SELL	$29.86 - $62.36 $782,511 - $1.63 Million	-26,206 Reduced 39.85%	39,552 $1.53 Million
Q1 2022 May 16, 2022	BUY	$53.73 - $82.16 $1.46 Million - $2.23 Million	27,174 Added 70.43%	65,758 $3.77 Million
Q4 2021 Feb 14, 2022	SELL	$68.02 - $99.06 $691,559 - $1.01 Million	-10,167 Reduced 20.85%	38,584 $3.08 Million
Q3 2021 Nov 15, 2021	BUY	$84.37 - $133.6 $1.67 Million - $2.64 Million	19,781 Added 68.28%	48,751 $4.24 Million
Q2 2021 Aug 13, 2021	SELL	$64.12 - $128.71 $612,923 - $1.23 Million	-9,559 Reduced 24.81%	28,970 $3.73 Million
Q1 2021 May 12, 2021	BUY	$71.28 - $120.75 $1.2 Million - $2.03 Million	16,773 Added 77.1%	38,529 $3.08 Million
Q4 2020 Feb 11, 2021	BUY	$22.24 - $95.63 $384,640 - $1.65 Million	17,295 Added 387.69%	21,756 $1.78 Million
Q3 2020 Nov 12, 2020	SELL	$19.0 - $30.57 $52,706 - $84,801	-2,774 Reduced 38.34%	4,461 $110,000
Q2 2020 Jul 31, 2020	BUY	$15.26 - $28.66 $98,198 - $184,427	6,435 Added 804.37%	7,235 $203,000
Q1 2020 May 01, 2020	BUY	$13.31 - $29.2 $10,648 - $23,360	800 New	800 $14,000

Others Institutions Holding BEAM

# of Institutions

258

Shares Held

93.6M

Call Options Held

425K

Put Options Held

309K

View Full List

About Beam Therapeutics Inc.

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.11B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

More about BEAM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account